Endothelin-1 increases expression and activity of arginase 2 via ETB receptors and is co-expressed with arginase 2 in human atherosclerotic plaques.

[1]  G. Bergström,et al.  Novel Multiomics Profiling of Human Carotid Atherosclerotic Plaques and Plasma Reveals Biliverdin Reductase B as a Marker of Intraplaque Hemorrhage , 2018, JACC. Basic to translational science.

[2]  C. Östenson,et al.  Erythrocytes From Patients With Type 2 Diabetes Induce Endothelial Dysfunction Via Arginase I. , 2018, Journal of the American College of Cardiology.

[3]  S. Catrina,et al.  Red Blood Cells in Type 2 Diabetes Impair Cardiac Post-Ischemic Recovery Through an Arginase-Dependent Modulation of Nitric Oxide Synthase and Reactive Oxygen Species , 2018, JACC. Basic to translational science.

[4]  H. Griffiths,et al.  Redox regulation in metabolic programming and inflammation , 2017, Redox biology.

[5]  M. Cutolo,et al.  Dual endothelin receptor antagonists contrast the effects induced by endothelin-1 on cultured human microvascular endothelial cells. , 2017, Clinical and experimental rheumatology.

[6]  A. Gabrielsen,et al.  Gene expression signatures, pathways and networks in carotid atherosclerosis , 2016, Journal of internal medicine.

[7]  W. Park,et al.  Endothelial Dysfunction: Clinical Implications in Cardiovascular Disease and Therapeutic Approaches , 2015, Journal of Korean medical science.

[8]  K. Bibbins-Domingo,et al.  Global Overview of the Epidemiology of Atherosclerotic Cardiovascular Disease. , 2015, Archives of medical research.

[9]  M. Goulart,et al.  Arginase as a Critical Prooxidant Mediator in the Binomial Endothelial Dysfunction-Atherosclerosis , 2015, Oxidative medicine and cellular longevity.

[10]  J. Pernow,et al.  Selective endothelin ETA and dual ET(A)/ET(B) receptor blockade improve endothelium-dependent vasodilatation in patients with type 2 diabetes and coronary artery disease. , 2014, Life sciences.

[11]  J. Montani,et al.  ARG2 impairs endothelial autophagy through regulation of MTOR and PRKAA/AMPK signaling in advanced atherosclerosis , 2014, Autophagy.

[12]  J. Pernow,et al.  Effect of Arginase Inhibition on Ischemia-Reperfusion Injury in Patients with Coronary Artery Disease with and without Diabetes Mellitus , 2014, PloS one.

[13]  F. Pontén,et al.  Profiling of Atherosclerotic Lesions by Gene and Tissue Microarrays Reveals PCSK6 as a Novel Protease in Unstable Carotid Atherosclerosis , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[14]  J. Lundberg,et al.  Arginase regulates red blood cell nitric oxide synthase and export of cardioprotective nitric oxide bioactivity , 2013, Proceedings of the National Academy of Sciences.

[15]  D. Berkowitz,et al.  Development of Novel Arginase Inhibitors for Therapy of Endothelial Dysfunction , 2013, Front. Immunol..

[16]  C. Jung,et al.  Arginase as a potential target in the treatment of cardiovascular disease: reversal of arginine steal? , 2013, Cardiovascular research.

[17]  C. Jung,et al.  Arginase Inhibition Improves Endothelial Function in Patients With Coronary Artery Disease and Type 2 Diabetes Mellitus , 2012, Circulation.

[18]  J. Pernow,et al.  New perspectives on endothelin-1 in atherosclerosis and diabetes mellitus. , 2012, Life sciences.

[19]  M. Crabtree,et al.  Endothelin-1 increases superoxide production in human coronary artery bypass grafts. , 2012, Life sciences.

[20]  J. Montani,et al.  Arginase II Promotes Macrophage Inflammatory Responses Through Mitochondrial Reactive Oxygen Species, Contributing to Insulin Resistance and Atherogenesis , 2012, Journal of the American Heart Association.

[21]  H. Westerblad,et al.  Local Arginase Inhibition during Early Reperfusion Mediates Cardioprotection via Increased Nitric Oxide Production , 2012, PloS one.

[22]  Lasse Folkersen,et al.  Prediction of Ischemic Events on the Basis of Transcriptomic and Genomic Profiling in Patients Undergoing Carotid Endarterectomy , 2012, Molecular medicine.

[23]  A. Gabrielsen,et al.  Correlations between clinical variables and gene-expression profiles in carotid plaque instability. , 2011, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[24]  A. Shoukas,et al.  OxLDL-dependent activation of arginase II is dependent on the LOX-1 receptor and downstream RhoA signaling. , 2011, Atherosclerosis.

[25]  M. Dashwood,et al.  Further evidence for a role of endothelin-1 (ET-1) in critical limb ischaemia , 2011, Journal of Cell Communication and Signaling.

[26]  Olivier Levillain,et al.  Macrophage Plasticity in Experimental Atherosclerosis , 2010, PloS one.

[27]  P. Libby,et al.  The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models , 2008, Nature Reviews Immunology.

[28]  A. Shoukas,et al.  Endothelial Arginase II: A Novel Target for the Treatment of Atherosclerosis , 2008, Circulation research.

[29]  T. Mukherjee,et al.  Modulating role of estradiol on arginase II expression in hyperlipidemic rabbits as an atheroprotective mechanism , 2006, Proceedings of the National Academy of Sciences.

[30]  J. Pernow,et al.  The endothelin-1 receptor antagonist bosentan protects against ischaemia/reperfusion-induced endothelial dysfunction in humans. , 2005, Clinical science.

[31]  A. Zeiher,et al.  Endothelial Function: Cardiac Events , 2005, Circulation.

[32]  C. Ihling,et al.  Endothelin-1 and endothelin converting enzyme-1 in human atherosclerosis--novel targets for pharmacotherapy in atherosclerosis. , 2004, Current vascular pharmacology.

[33]  R. Peto,et al.  Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial , 2004, The Lancet.

[34]  J. Keaney,et al.  The clinical implications of endothelial dysfunction. , 2003, Journal of the American College of Cardiology.

[35]  L. Hansson,et al.  Combined Endothelin Receptor Blockade Evokes Enhanced Vasodilatation in Patients With Atherosclerosis , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[36]  P. Rothwell,et al.  Angiographically defined collateral circulation and risk of stroke in patients with severe carotid artery stenosis. North American Symptomatic Carotid Endarterectomy Trial (NASCET) Group. , 2000, Stroke.

[37]  T. Lüscher,et al.  Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[38]  M. Modolell,et al.  Arginase induction by suppressors of nitric oxide synthesis (IL-4, IL-10 and PGE2) in murine bone-marrow-derived macrophages. , 1995, Biochemical and biophysical research communications.

[39]  A. Zeiher,et al.  Increased tissue endothelin immunoreactivity in atherosclerotic lesions associated with acute coronary syndromes , 1994, The Lancet.

[40]  V. Fuster,et al.  Circulating and Tissue Endothelin Immunoreactivit in Hypercholesterolemic Pigs , 1993, Circulation.